Skip to search formSkip to main contentSkip to account menu

KIAA0100 gene

Known as: CT101, BREAST CANCER-OVEREXPRESSED GENE 1, BCOX1 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Abstract CT101: D-BEYOND: A window of opportunity trial evaluating denosumab, a RANK-ligand (RANKL) inhibitor and its biological effects in young pre-menopausal women diagnosed with early breast…
Background Breast cancer (BC) in young women has unique biology and poor prognosis. Previous reports suggest that they often… 
2018
2018
Mass Spectrometry-Based Immunopeptidome Analysis of Acute Myeloid Leukemia Cells Under Decitabine Treatment Delineates Induced Presentation of Cancer/Testis Antigens on HLA Class I Molecules
In recent years, therapeutic approaches for acute myeloid leukemia (AML) have been improved, however the disease is still… 
2017
2017
Preparation of monoclonal antibody against human KIAA0100 protein and Northern blot analysis of human KIAA0100 gene
2016
2016
Abstract CT101: NCI-molecular analysis for therapy choice (NCI-MATCH) clinical trial: interim analysis
The NCI MATCH is an efficacy signal-finding trial to identify molecular alterations that can be matched to targeted treatments in… 
Review
2015
Review
2015
Abstract CT101: Phase III study of pembrolizumab (MK-3475) versus ipilimumab in patients with ipilimumab-naive advanced melanoma
Background: Ipilimumab (IPI; anti-CTLA4) and pembrolizumab (PEMBRO; anti-PD-1) are checkpoint inhibitors that stimulate immune… 
2015
2015
MicroRNA-195 suppresses tumor cell proliferation and metastasis by directly targeting BCOX1 in prostate carcinoma
Elucidation of the downstream targets regulated by the metastasis-suppressive miRNAs can shed light on the metastatic processes… 
2003
2003
Identification of Widely Applicable Tumor-Associated Antigens for Breast Cancer Immunotherapy
Abstract : This study is the initial phase (the 1st year) of a feasibility study of a novel immunotherapeutic strategy for the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)